Navigation Links
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Date:10/5/2009

17 of these patients were deemed evaluable. In this initial cohort, 11 of the 17 evaluable patients achieved an objective tumor response by the time that treatment with the combination of bavituximab, carboplatin and paclitaxel was completed. These initial results exceeded the pre-specified endpoint needed to expand the trial, which then enrolled an additional 28 patients to reach the planned study total of 49 patients.

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as a monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

Lung cancer is a major cause of cancer deaths worldwide. According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in men and women in the U.S. and is the leading cause of cancer deaths. It estimates that in 2009, there will be approximately 219,440 new cases of lung cancer in the U.S. and an estimated 159,000 lung cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By masking PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab is being tested in combination with chemotherapy in three Phase
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , 23 de julio de 2014 /PRNewswire/ ... o la Compañía) ha anunciado hoy una asociación ... (ABIA o el Instituto), para el ... un dispositivo de terapia de señal bioeléctrica (el ... El Instituto, que tiene una importante experiencia ...
(Date:7/23/2014)... , July 23, 2014 regulated information ... research and development pipeline with positive topline results ... brivaracetam . This study was designed to evaluate the ... and 200 mg/day, without titration) compared to placebo, ... with partial-onset seizures, not fully controlled despite treatment ...
(Date:7/23/2014)... California (PRWEB) July 23, 2014 With the ... in HD resolution for more than 15 minutes, Fastec Imaging ... the world of high speed imaging. “Finally, a high speed ... camera we use in our everyday lives.” proclaims Matt Kearney, ... Fastec has always been to demystify and simplify the traditionally ...
(Date:7/22/2014)... (PR Web) July 21, 2014 (PRWEB) July 23, ... for Biomaterials, at Rutgers University. , The ... and ideas across the full spectrum of scientists ... selected research and development topics that represent the ... have been programmed to:,     Provide ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2
... March 4 SGX Pharmaceuticals,(Nasdaq: SGXP ) ... and,full year 2007 on Wednesday, March 12, 2008. ... call and webcast at 8:00 a.m. Pacific Time.,Mike ... Myers, Chief,Financial Officer, will host the conference call ...
... PHILADELPHIA - For centuries, engineers have bent and torn ... scientists at the University of Pennsylvania School of Engineering ... at nanoscale sizes in the form of wires a ... has enable Penn engineers to construct a theoretical model ...
... Achieves 2007 Net Income of $13.1 Million, DUBLIN, ... a pharmaceutical company dedicated to the discovery, rapid,development and ... reported financial results for the fourth,quarter and year ended ... for the 2007 fourth quarter of $5.1,million, or $0.09 ...
Cached Biology Technology:SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results 2Surface dislocation nucleation: Strength is but skin deep at the nanoscale, Penn engineers discover 2SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 2SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 3SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 4SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 5SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 6SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 7SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 8SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 9SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 10SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 11SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 12
(Date:7/23/2014)... alongside decades of in-depth monitoring, has provided unique ... a population of top-predators. Published in Nature ... seals have significantly altered in accordance with changes ... conditions. Despite a shift in the population towards ... through generations, leaving the population in decline. ...
(Date:7/23/2014)... a high health risk warning for Yellowknife and surrounding ... to forest fires. In the image taken by ... normal wind patterns. Fire is an obvious health ... not quite so obvious and its effects are insidious. ... (forest, brush, crop, structure, tires, waste or wood burning) ...
(Date:7/23/2014)... 780 million people around the world have no access ... Organization (WHO), 3.4 million people die from water-related diseases ... goal of making a contribution to solving this problem. ... Stark, head of the Functional Materials Laboratory, the 23-year-old ... a prototype. , "What makes our DrinkPure filter unique ...
Breaking Biology News(10 mins):Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3ETH student develops filter for clean water around the world 2
... University of California, San Diego NanoEngineers won a ... develop the tools to manufacture biodegradable frames around which ... grow. Developing methods for growing tissues that mimic nature,s ... efforts to grow replacement cardiac tissues for people who ...
... University of Illinois researchers are using a new kind of ... the relationship between cell mass and growth rate. ... professor Rashid Bashir, published its results in the online early ... Sciences . "It,s merging micro-scale engineering and cell biology," ...
... Nov. 15, 2010 Tiny molecules called microRNAs ... labor, raising the prospect that RNA-based drugs might be ... Medical Center have discovered in a preclinical study. ... controls labor, so with future research we might have ...
Cached Biology News:Nanoengineers aim to grow tissues with functional blood vessels 2Nanoengineers aim to grow tissues with functional blood vessels 3Microsensors offer first look at whether cell mass affects growth rate 2Tiny RNA molecules control labor, may be key to blocking premature birth 2
... Expansion Kit - Neurosphere is a system designed ... expansion as neurospheres in a serum free environment. ... Media Supplement, which has been optimized for neural ... . (1996) Genes & Development 10 :3129). ...
Request Info...
... RQ1 RNase-Free DNase is a ... single-stranded or double-stranded DNA to produce ... for use in applications where maintaining ... RQ1 DNase is qualified for use ...
... Polymerase I catalyzes the template-directed polymerization of ... direction. DNA Polymerase I possesses a 3?5 ... the error rate during DNA replication, and ... enables the enzyme to replace nucleotides in ...
Biology Products: